EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models

Lung adenocarcinoma patients harboring kinase domain mutations in Epidermal growth factor receptor (EGFR) have significant clinical benefit from EGFR-targeted tyrosine kinase inhibitors (TKIs). Although a majority of patients experience clinical symptomatic benefit immediately, an objective response...

Descripción completa

Detalles Bibliográficos
Autores principales: Venugopalan, Abhilash, Lee, Min-Jung, Niu, Gang, Medina-Echeverz, José, Tomita, Yusuke, Lizak, Martin J., Cultraro, Constance M., Simpson, Robert Mark, Chen, Xiaoyuan, Trepel, Jane B., Guha, Udayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338915/
https://www.ncbi.nlm.nih.gov/pubmed/27494838
http://dx.doi.org/10.18632/oncotarget.11021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338915/
https://www.ncbi.nlm.nih.gov/pubmed/27494838
http://dx.doi.org/10.18632/oncotarget.11021

Ejemplares similares